Ohio State Experts Using New Method for Lung Cancer Diagnosis

Publication
Article
OncologyONCOLOGY Vol 22 No 5
Volume 22
Issue 5

Interventional pulmonologists at The Ohio State University Medical Center are using an improved and more efficient technique to diagnose lung cancer. Attached at the tip of the bronchoscope, an ultrasound probe identifies the location of the cancerous masses in a patient's chest, allowing for an accurate biopsy, or tissue sample, under ultrasound guidance.

Interventional pulmonologists at The Ohio State University Medical Center are using an improved and more efficient technique to diagnose lung cancer. Attached at the tip of the bronchoscope, an ultrasound probe identifies the location of the cancerous masses in a patient's chest, allowing for an accurate biopsy, or tissue sample, under ultrasound guidance.

Traditionally, chest biopsies were obtained through a small incision in the neck. This technique also required an operating room and general anesthesia. In addition, pulmonologists could also obtain a diagnosis using a biopsy needle through a bronchoscope. However, there was no real-time guidance and the site of the tumor would be determined after reviewing a patient's x-ray or other diagnostic scan.

"Studies have shown that accurate staging, along with diagnosis of lung cancer, can be done without any surgical procedures," says Dr. Shaheen Islam, an interventional pulmonologist and critical care specialist at Ohio State's Medical Center.

Outpatient Procedure

"Some lung cancer patients also have emphysema from smoking, which does not make them very good surgical candidates," adds Islam. "Using this new technique allows patients for an accurate staging through an outpatient procedure with minimal, conscious sedation, so that appropriate treatment can be offered."

Lung cancer is the leading cause of cancer deaths in the United States, killing over 160,000 people yearly. Approximately 213,000 people are diagnosed with lung cancer each year, and 85% of those diagnosed with the disease will die within the first 5 years of diagnosis.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Related Content